L
Lundbeck
Lundbeck is a global pharmaceutical company specialized in brain diseases
About Lundbeck
The story begins in 1915 when Hans Lundbeck founded a trading company in Copenhagen, Denmark. Initially, the business dealt in a variety of goods, from machinery and biscuits to synthetic sweeteners. It wasn't until 1924 that the company entered the pharmaceutical space, importing medicines and cosmetics. This pivot marked the first step towards the global specialty pharmaceutical company it is today. Throughout the following decades, Lundbeck established its own research and development capabilities, focusing on what would become its core mission: tackling brain diseases. This strategic shift from a trading agency to a research-driven pharmaceutical firm was crucial. By the 1950s, the company had developed its first breakthrough drug for schizophrenia, laying the foundation for its future in neuroscience. A significant milestone in the company's journey occurred in June 1999 when Lundbeck was listed on the Copenhagen Stock Exchange. This Initial Public Offering provided the capital to further fuel its international expansion and R&D pipeline. The majority of the company's shares, however, remained with the Lundbeck Foundation, ensuring a long-term commitment to its research-focused mission. Today, Lundbeck stands as a testament to strategic evolution, from a small Danish trading house to a global leader dedicated to restoring brain health.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1915
- Headquarters
- Copenhagen, Denmark
- Listing
- IPO 2000
- Employees
- 6,033
- Open positions
- 147
- Dealroom signal
- 33.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Charity, Risk Management, Biotechnology, Neurology, Health Diagnostics, Horizon Europe
- Client focus
- b2b
- Investment activity
- 9 companies, latest Oct 2024
- Capital deployed
- $141M
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBT✓Debt | Jun 2026 | $770M | — | Bank of America · BNP Paribas · Danske Bank · Jyske Bank | ↗ |
| GRANT✓Other financing | Mar 2020 | — | — | Michael J. Fox Foundation for Parkinson's Research | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Lundbeck is 120K monthly website visits, up 0% over the last three months. Lundbeck's team grew 10.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Longboard PharmaceuticalsSan Diego, United StatesA clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases
$2.1Bvaluation
Alder BiopharmaceuticalsBothell, United StatesA biopharmaceutical company, Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics
$1.9Bvaluation
AT
Abide TherapeuticsCopenhagen, DenmarkPharmaceutical company developing serine hydrolase inhibitors
$250Mvaluation
Prexton therapeuticsOss, NetherlandsIntegrates molecular, behavioral and chemistry technologies to address Parkinson’s disease and other brain disorders
$1Bvaluation
BenevolentAILondon, United KingdomBenevolentAI is a leading, clinical-stage AI-enabled drug discovery company
−$28Mvaluation
Chelsea Therapeutics InternationalCharlotte, United StatesA pharmaceutical company developing and commercializing therapeutics for a variety of human diseases
$658Mvaluation
NaurexEvanston, United StatesDeveloping novel modulators of the NMDA receptor to treat challenging diseases of the brain and central nervous system
$560Mvaluation
ProximagenBabraham, United KingdomDrug discovery for central nervous system disorders
$64Mvaluation
Ovation PharmaceuticalsDeerfield, United States
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Michael J. Fox Foundation for Parkinson's Research
Series B and later6 investors entered at this stage
Bank of America
BNP Paribas
Danske Bank
Jyske Bank
Nordea
SEB
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lundbeck on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lundbeck’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.